CoChat

Microglia Phenotypes in Aging and Neurodegenerative Diseases

Open access

The DOI matches its Crossref record; the references it cites are not checked yet.

Abstract

Neuroinflammation is a hallmark of many neurodegenerative diseases (NDs) and plays a fundamental role in mediating the onset and progression of disease. Microglia, which function as first-line immune guardians of the central nervous system (CNS), are the central drivers of neuroinflammation. Numerous human postmortem studies and in vivo imaging analyses have shown chronically activated microglia in patients with various acute and chronic neuropathological diseases. While microglial activation is a common feature of many NDs, the exact role of microglia in various pathological states is complex and often contradictory. However, there is a consensus that microglia play a biphasic role in pathological conditions, with detrimental and protective phenotypes, and the overall response of microglia and the activation of different phenotypes depends on the nature and duration of the inflammatory insult, as well as the stage of disease development. This review provides a comprehensive overview of current research on the various microglia phenotypes and inflammatory responses in health, aging, and NDs, with a special emphasis on the heterogeneous phenotypic response of microglia in acute and chronic diseases such as hemorrhagic stroke (HS), Alzheimer’s disease (AD), and Parkinson’s disease (PD). The primary focus is translational research in preclinical animal models and bulk/single-cell transcriptome studies in human postmortem samples. Additionally, this review covers key microglial receptors and signaling pathways that are potential therapeutic targets to regulate microglial inflammatory responses during aging and in NDs. Additionally, age-, sex-, and species-specific microglial differences will be briefly reviewed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/cells11132091

Cites

Statistics

Figures

Figure 1 Microglial activation phenotypes and functions. Microglia can be polarized from a resting state (M0 microglia) to two main activation phenotypes, classically activated M1 microglia and alternatively activated M2 microglia, which are induced by interaction of inflammatory molecules with their respective cognate receptors. These microglia phenotypes exhibit a variety of phenotypic markers that are expressed intracellularly or on the cell surface, as well as molecules that are secreted from the cell, such as chemokines, cytokines, and other effector molecules. The M2 phenotype is further subdivided into three subtypes: M2a (alternatively activated state), M2b (type II activation phenotype), and M2c (acquired deactivation state). The M2b subtype shares similar features as M1 microglia and is induced by inflammatory molecules. The phenotypes of M1 and M2 microglia perform distinct functions that can be neurotoxic or neuroprotective, respectively. Figure created using BioRender.com (accessed on 14 April 2022).
Figure 1 Microglial activation phenotypes and functions. Microglia can be polarized from a resting state (M0 microglia) to two main activation phenotypes, classically activated M1 microglia and alternatively activated M2 microglia, which are induced by interaction of inflammatory molecules with their respective cognate receptors. These microglia phenotypes exhibit a variety of phenotypic markers that are expressed intracellularly or on the cell surface, as well as molecules that are secreted from the cell, such as chemokines, cytokines, and other effector molecules. The M2 phenotype is further subdivided into three subtypes: M2a (alternatively activated state), M2b (type II activation phenotype), and M2c (acquired deactivation state). The M2b subtype shares similar features as M1 microglia and is induced by inflammatory molecules. The phenotypes of M1 and M2 microglia perform distinct functions that can be neurotoxic or neuroprotective, respectively. Figure created using BioRender.com (accessed on 14 April 2022).CC BY · PubMed Central
Figure 2 Age-dependent microglial changes implicated in neurodegenerative diseases. During aging, microglia exhibit alterations in their morphology, phenotypes, inflammatory response, and overall functional response. Healthy adult microglia with normal branched processes can effectively survey the brain microenvironment, and upon encountering infections, injury, and inflammatory agents, they change morphology and execute effector functions by becoming transiently activated. In comparison, old microglia have a dystrophic morphology associated with cellular senescence and exhibit a primed phenotype in which they are hypersensitive to environmental changes and produce large amounts of M1-like pro-inflammatory and neurotoxic mediators which contribute to chronic neuroinflammation. Age-associated loss of endogenous microglial regulatory pathways, such as CX3CR1-CX3CL1 signaling and TGF-β signaling, impairs the ability of microglia to regulate inflammatory responses. Aging is also associated with a decline in calcium response, motility, and phagocytosis functions, all of which impair microglial clearance of injured cells, tissue debris, and pathogenic proteins. However, complement-mediated phagocytosis mechanisms are upregulated in aged microglia and contribute to the loss of healthy neurons. These age-related microglial dysfunctions, combined with a chronic stress environment, brain trauma, or genetic predisposing factors, can contribute to the progressive onset of neurodegenerative diseases. AD: Alzheimer’s disease; PD: Parkinson’s disease; HS: Hemorrhagic stroke. Figure created using BioRender.com (accessed on 14 April 2022).
Figure 2 Age-dependent microglial changes implicated in neurodegenerative diseases. During aging, microglia exhibit alterations in their morphology, phenotypes, inflammatory response, and overall functional response. Healthy adult microglia with normal branched processes can effectively survey the brain microenvironment, and upon encountering infections, injury, and inflammatory agents, they change morphology and execute effector functions by becoming transiently activated. In comparison, old microglia have a dystrophic morphology associated with cellular senescence and exhibit a primed phenotype in which they are hypersensitive to environmental changes and produce large amounts of M1-like pro-inflammatory and neurotoxic mediators which contribute to chronic neuroinflammation. Age-associated loss of endogenous microglial regulatory pathways, such as CX3CR1-CX3CL1 signaling and TGF-β signaling, impairs the ability of microglia to regulate inflammatory responses. Aging is also associated with a decline in calcium response, motility, and phagocytosis functions, all of which impair microglial clearance of injured cells, tissue debris, and pathogenic proteins. However, complement-mediated phagocytosis mechanisms are upregulated in aged microglia and contribute to the loss of healthy neurons. These age-related microglial dysfunctions, combined with a chronic stress environment, brain trauma, or genetic predisposing factors, can contribute to the progressive onset of neurodegenerative diseases. AD: Alzheimer’s disease; PD: Parkinson’s disease; HS: Hemorrhagic stroke. Figure created using BioRender.com (accessed on 14 April 2022).CC BY · PubMed Central
Figure 3 Microglial functions and diverse activation responses in neurodegenerative diseases. (A) Summary of the major activation mediators and receptors involved in microglial responses to Alzheimer’s disease (AD), Parkinson’s disease (PD), and hemorrhagic stroke (HS). Microglia can be activated directly by disease-specific triggers such as amyloid-β (Aβ) in AD, α-synuclein (α-syn) in PD, or hematoma products such as heme/hemoglobin and thrombin in HS. Various shared microglial receptors interact with these pathogenic molecules, and their overall response depends on the nature of the disease, the stage of the disease, and the specific molecular trigger. Microglial response is also modulated by other mediators such as cytokines present in the cerebrospinal fluid, damage-associated molecules (DAMPs), such as ADP, released from injured neurons, and neuron-derived endogenous signals such as CX3CL1. In general, microglial response can be pro-inflammatory/neurotoxic (+) or anti-inflammatory/neuroprotective (−). Activation of PAR-1, RAGE, CD36, and TLR receptors generally promotes pro-inflammatory responses by activating a range of pro-inflammatory pathways, such as JAK/STAT, MAPK, or NFκB, as well as the NLRP3 inflammasome. These diverse pro-inflammatory pathways can also interact synergistically, promoting chronic neuroinflammation. In contrast, activation of P2YR12 and CX3CR1 negatively regulates microglial activation and pro-inflammatory responses and generally mediates protective functions. Similarly, activation of TREM2 and other scavenger receptors induces microglial phagocytosis of Aβ and other pathogenic proteins, aiding in their clearance. These two generally distinct microglial responses also antagonize one another; degradation of abnormal proteins and pathogenic mediators helps limit chronic neuroinflammation, while pro-inflammatory responses can compromise the microglial phagocytosis response. (B) Summary of the role of microglia phenotypes in the progression of neurodegenerative diseases. In HS, microglia can be activated by thrombin or heme or indirectly by DAMPs from injured neurons, and a sustained microglial pro-inflammatory response contributes to secondary neurodegeneration in areas outside the initial injury zone. Pro-inflammatory microglial responses in PD and AD trigger post-translational modifications (PTMs) and misfolding and aggregation of α-syn and Aβ, that can contribute to the formation of amyloid plaques and Lewy bodies, thereby contributing to disease progression. Pro-inflammatory microglia also induce tau phosphorylation and subsequent aggregation, which promotes neurofibrillary tangle formation (NFT) and overall disease progression. Furthermore, pro-inflammatory microglia exhibit a dysregulated phagocytosis response, limiting the clearance of hematoma products and misfolded proteins that contribute to disease progression. On the contrary, anti-inflammatory/phagocytic microglia phenotypes mediate protective roles and limit disease progression by promoting tissue recovery. Figure created using BioRender.com (accessed on 14 April 2022).
Figure 3 Microglial functions and diverse activation responses in neurodegenerative diseases. (A) Summary of the major activation mediators and receptors involved in microglial responses to Alzheimer’s disease (AD), Parkinson’s disease (PD), and hemorrhagic stroke (HS). Microglia can be activated directly by disease-specific triggers such as amyloid-β (Aβ) in AD, α-synuclein (α-syn) in PD, or hematoma products such as heme/hemoglobin and thrombin in HS. Various shared microglial receptors interact with these pathogenic molecules, and their overall response depends on the nature of the disease, the stage of the disease, and the specific molecular trigger. Microglial response is also modulated by other mediators such as cytokines present in the cerebrospinal fluid, damage-associated molecules (DAMPs), such as ADP, released from injured neurons, and neuron-derived endogenous signals such as CX3CL1. In general, microglial response can be pro-inflammatory/neurotoxic (+) or anti-inflammatory/neuroprotective (−). Activation of PAR-1, RAGE, CD36, and TLR receptors generally promotes pro-inflammatory responses by activating a range of pro-inflammatory pathways, such as JAK/STAT, MAPK, or NFκB, as well as the NLRP3 inflammasome. These diverse pro-inflammatory pathways can also interact synergistically, promoting chronic neuroinflammation. In contrast, activation of P2YR12 and CX3CR1 negatively regulates microglial activation and pro-inflammatory responses and generally mediates protective functions. Similarly, activation of TREM2 and other scavenger receptors induces microglial phagocytosis of Aβ and other pathogenic proteins, aiding in their clearance. These two generally distinct microglial responses also antagonize one another; degradation of abnormal proteins and pathogenic mediators helps limit chronic neuroinflammation, while pro-inflammatory responses can compromise the microglial phagocytosis response. (B) Summary of the role of microglia phenotypes in the progression of neurodegenerative diseases. In HS, microglia can be activated by thrombin or heme or indirectly by DAMPs from injured neurons, and a sustained microglial pro-inflammatory response contributes to secondary neurodegeneration in areas outside the initial injury zone. Pro-inflammatory microglial responses in PD and AD trigger post-translational modifications (PTMs) and misfolding and aggregation of α-syn and Aβ, that can contribute to the formation of amyloid plaques and Lewy bodies, thereby contributing to disease progression. Pro-inflammatory microglia also induce tau phosphorylation and subsequent aggregation, which promotes neurofibrillary tangle formation (NFT) and overall disease progression. Furthermore, pro-inflammatory microglia exhibit a dysregulated phagocytosis response, limiting the clearance of hematoma products and misfolded proteins that contribute to disease progression. On the contrary, anti-inflammatory/phagocytic microglia phenotypes mediate protective roles and limit disease progression by promoting tissue recovery. Figure created using BioRender.com (accessed on 14 April 2022).CC BY · PubMed Central
Figure 4 Innovative tools to study human microglia in neurodegenerative diseases. (A) Single-cell sequencing can be performed by isolating single cells from live or postmortem brains. This tool assists in characterizing the gene expression profiles of various cell types, which helps to understand the heterogeneous phenotypes of microglia in human diseases. (B) The generation of microglia-like cells from human-induced pluripotent stem cells (hiPSCs) has advanced mechanistic studies. iPSC can be derived from patients with neurodegenerative diseases or can be genetically modified to study human microglia responses in a specific disease environment. iPSC-derived microglia can also be co-cultured in two/three-dimensional systems or incorporated into brain organoids to study complex interactions of microglia with neurons and other cells. Brain-on-a-Chip technology employs a continuous flow of microscopic fluid in organoid systems, which enables the addition of extracellular matrix components to mimic the complex properties of the brain or incorporates pathogenic stimuli to emulate disease-specific brain microenvironment. Humanized microglia models, created through xenotransplantation of human iPSC-derived microglia models, help to study human microglia in intact models, and this technology is beneficial for translational research, such as therapeutic drug testing. Figure created using BioRender.com (accessed on 14 April 2022).
Figure 4 Innovative tools to study human microglia in neurodegenerative diseases. (A) Single-cell sequencing can be performed by isolating single cells from live or postmortem brains. This tool assists in characterizing the gene expression profiles of various cell types, which helps to understand the heterogeneous phenotypes of microglia in human diseases. (B) The generation of microglia-like cells from human-induced pluripotent stem cells (hiPSCs) has advanced mechanistic studies. iPSC can be derived from patients with neurodegenerative diseases or can be genetically modified to study human microglia responses in a specific disease environment. iPSC-derived microglia can also be co-cultured in two/three-dimensional systems or incorporated into brain organoids to study complex interactions of microglia with neurons and other cells. Brain-on-a-Chip technology employs a continuous flow of microscopic fluid in organoid systems, which enables the addition of extracellular matrix components to mimic the complex properties of the brain or incorporates pathogenic stimuli to emulate disease-specific brain microenvironment. Humanized microglia models, created through xenotransplantation of human iPSC-derived microglia models, help to study human microglia in intact models, and this technology is beneficial for translational research, such as therapeutic drug testing. Figure created using BioRender.com (accessed on 14 April 2022).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

The citation lists are queued

They are fetched later and appear here then.

References 435 · Cited by 336

Metadata

Authors
Wendimu, M. Y., & Hooks, S. B.
Affiliations
University of Georgia (US)
Corresponding author
Hooks, Shelley B.
Venue
Cells
Publisher
MDPI AG
Published
2022-06-30
Volume
11
Issue
13
Pages
2091
ISSN
2073-4409 (ISSN-L)
OpenAlex
W4283757722
Cited by
336
References
435
Citations by year
2026: 80 · 2025: 99 · 2024: 97 · 2023: 52 · 2022: 8
FWCI
6.58
Type
journal article
Language
en
Open access
Locations
  • Cells (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
the National Institutes of Health (NS109303, AG064416)
Topics
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
Keywords
microglia, microglial phenotype, neuroinflammation, aging, neurodegenerative diseases, hemorrhagic stroke, Alzheimer's disease, Parkinson's disease, microglial receptors, single-cell transcriptomics, postmortem brain, sex differences, age differences, species differences, microglial activation
MeSH terms
Animals, Central Nervous System, Parkinson Disease, Phenotype, Microglia, Neurodegenerative Diseases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Microglia Phenotypes in Aging and Neurodegenerative Diseases. https://app.cochat.ai/papers/10.3390/cells11132091
The paper
Wendimu, M. Y., & Hooks, S. B. (2022). Microglia Phenotypes in Aging and Neurodegenerative Diseases. Cells. https://doi.org/10.3390/cells11132091

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.